内容: The objective of this study is to identify the antioxidant peptides from shrimp by-products and clarify the underlying protective mechanism involved in HepG2 cells with oxidative stress induced by H2O2. Protein from shrimp by-products was hydrolyzed by three enzymes (neutral protase, alcalase, and Protamex) and the hydrolysates were separated by using Sephadex G-15 gel filtration, among which the A3 (fraction of alcalase-hydrolysate) displayed a significant 1,1-diphenyl-2-picrylhydrazyl radical and 2,2′-azino-bis-(3- ethylbenzothiazoline-6-sulfonic acid) cation radical scavenging ability. A total of 3 480 peptides were identified through nano-high performance liquid chromatography-tandem mass spectrometry, with the prediction of five discovered antioxidant peptides (DYPLVPPYF, HFVPVYEGF, GFPPFTGGPFR, EGYPFNPLL, and RVSDGPWLGR). Notably, HFVPVYEGF and EGYPFNPLL emerged as the potent antioxidant peptide, displaying lower half maximal inhibitory concentration. Furthermore, HFVPVYEGF and EGYPFNPLL obviously relieved oxidative stress in HepG2 cells, which strengthened the activity of total-antioxidant capocity, catalase, glutathione peroxidase, and superoxide dismutase, with diminishing the intensity of malondialdehyde and intracellular reactive oxygen species. Molecular docking results revel that HFVPVYEGF and EGYPFNPLL can bind to Kelch-like ECH-associated protein 1 with hydrophobic interactions. The results provided theoretical basis for the production and application of the by-product of shrimp. And a further study should be carried out to examine the bioavailability and in vivo activity of HFVPVYEGF and EGYPFNPLL which identified from shrimp by-products.

内容: This study aimed to use the Gene Expression Omnibus (GEO) database combined with network pharmacology technology to investigate the positive effect of galangin on alcoholic fatty liver disease (AFLD) and explore its potential mechanism. The study first screened the differential genes in ALFD mice through the GEO database, obtained the possible targets of galangin through the SwissTargetPrediction and PharmMapper databases, and then obtained the intersection of drug and disease targets through a Venn diagram to build a “drug-target-pathway-disease” network relationship diagram, and its possible molecular mechanisms were analyzed through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. The network pharmacology analysis identified 22 potential targets for galangin in the treatment of AFLD, and protein-protein interaction network analysis revealed that the top 5 targets were protein kinase B (AKT) 1, epidermal growth factor receptor, mitogen-activated protein kinase (MAPK) 3, myeloid cell leukemia 1, and KIT proto-oncogene receptor tyrosine kinase. The KEGG results showed that the treatment of AFLD by galangin may be related to the MAPK signaling pathway, cyclic adenosine monophosphate signaling pathway, Ras-related protein 1 signaling pathway and phosphoinositide 3 kinase/AKT signaling pathway. Therefore, the combination of GEO database and network pharmacology prediction results showed that galangin could alleviate alcoholic fatty liver and exert anti-inflammatory effects. It provides a theoretical basis for research on the mechanism of galangin in treating AFLD and other diseases.